73:@0.890196:0.957873:0.907378:0.957873:0.907378:0.938882:0.890196:0.938882:0.008591:0.008591
3:@0.941813:0.310836:0.963291:0.310836:0.963291:0.263358:0.941813:0.263358:0.021478
PATIENT-DERIVED OVARIAN CANCER ORGANOIDS MIMIC CLINICAL RESPONSE AND:@0.411230:0.057372:0.882353:0.057372:0.882353:0.040253:0.411230:0.040253:0.007583:0.007097:0.006387:0.003511:0.006985:0.008759:0.005640:0.005155:0.008423:0.006985:0.008423:0.003511:0.007620:0.006985:0.008423:0.002988:0.008328:0.006966:0.007919:0.008423:0.003511:0.007919:0.008759:0.002988:0.008178:0.007919:0.008759:0.008255:0.006985:0.008423:0.002988:0.008442:0.008311:0.008292:0.007919:0.008759:0.008442:0.003511:0.008423:0.007807:0.002988:0.011112:0.003511:0.011112:0.003511:0.008255:0.002988:0.008255:0.006481:0.003511:0.008759:0.003511:0.008177:0.007919:0.006294:0.002988:0.008423:0.006871:0.007807:0.008050:0.008442:0.008759:0.007807:0.006985:0.002801:0.007919:0.008759:0.008423
EXHIBIT HETEROGENEOUS INTER- AND INTRAPATIENT DRUG RESPONSES:@0.468171:0.073247:0.882352:0.073247:0.882352:0.056128:0.468171:0.056128:0.006985:0.007527:0.008685:0.003511:0.008236:0.003511:0.006201:0.002988:0.008685:0.006985:0.006387:0.006985:0.008309:0.008442:0.008404:0.006985:0.008759:0.006985:0.008442:0.008367:0.007807:0.002988:0.003511:0.008759:0.006387:0.006985:0.008423:0.005155:0.002800:0.007919:0.008759:0.008423:0.002988:0.003511:0.008759:0.006387:0.008423:0.007919:0.007581:0.007097:0.006387:0.003511:0.006985:0.008759:0.006201:0.002988:0.008423:0.008367:0.008367:0.008404:0.002988:0.008423:0.006873:0.007807:0.008050:0.008442:0.008759:0.007807:0.006871:0.007807
Moreover, we assessed if SVs (including gene fusions) in genes from the DGIdb resource :@0.147059:0.121273:0.886391:0.121273:0.886391:0.100900:0.147059:0.100900:0.018969:0.010843:0.007442:0.009108:0.010866:0.009633:0.009039:0.006255:0.004497:0.003766:0.014518:0.009039:0.003766:0.009291:0.007533:0.007875:0.009039:0.007531:0.007875:0.009108:0.011391:0.003766:0.005615:0.006209:0.003766:0.010112:0.015089:0.007670:0.003766:0.006939:0.005615:0.011596:0.008765:0.004908:0.011345:0.011391:0.005615:0.011459:0.009861:0.003766:0.009656:0.009039:0.011596:0.009039:0.003766:0.006366:0.011413:0.007601:0.005547:0.010843:0.011619:0.007670:0.006939:0.003766:0.005615:0.011756:0.003766:0.009656:0.009039:0.011596:0.009039:0.007670:0.003766:0.006414:0.007442:0.010843:0.017645:0.003766:0.006620:0.011299:0.009039:0.003766:0.016504:0.015682:0.006620:0.011322:0.011025:0.003766:0.007442:0.009039:0.007875:0.010820:0.011413:0.007442:0.008994:0.009039:0.004109
could be linked to differential drug response. In the related PDOs derived from the eight :@0.147059:0.141852:0.886414:0.141852:0.886414:0.121479:0.147059:0.121479:0.008994:0.010820:0.011550:0.005182:0.011391:0.003835:0.011254:0.009039:0.003835:0.005250:0.005615:0.011868:0.010272:0.009108:0.011391:0.003835:0.006209:0.011048:0.003835:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.005798:0.009405:0.005250:0.003835:0.011391:0.007967:0.011413:0.009861:0.003835:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.008743:0.004497:0.003835:0.006894:0.011756:0.003835:0.006620:0.011299:0.009039:0.003835:0.007442:0.008948:0.005433:0.008809:0.006211:0.009106:0.011391:0.003835:0.011664:0.016504:0.016253:0.007670:0.003835:0.011322:0.009039:0.007807:0.005547:0.009633:0.009108:0.011391:0.003835:0.006414:0.007442:0.010843:0.017645:0.003835:0.006620:0.011299:0.009039:0.003835:0.009039:0.005615:0.009930:0.011094:0.006437:0.004109
patients that exhibited differential drug response, no SVs were identified that could ex-:@0.147059:0.162431:0.882353:0.162431:0.882353:0.142058:0.147059:0.142058:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004953:0.006620:0.011391:0.008811:0.006437:0.004953:0.009108:0.010089:0.011459:0.005547:0.010820:0.005271:0.006211:0.009106:0.011391:0.004953:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.005798:0.009405:0.005250:0.004953:0.011391:0.007967:0.011413:0.009861:0.004953:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.008743:0.004497:0.004953:0.011596:0.011048:0.004953:0.010112:0.015089:0.007670:0.004953:0.014518:0.009039:0.007442:0.009039:0.004953:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.005684:0.005615:0.009108:0.011391:0.004953:0.006620:0.011391:0.008811:0.006437:0.004953:0.008994:0.010820:0.011550:0.005182:0.011391:0.004953:0.009108:0.010089:0.007533
plain phenotypic heterogeneity. In addition to genetic heterogeneity in genes reported to :@0.147059:0.183009:0.886464:0.183009:0.886464:0.162636:0.147059:0.162636:0.011162:0.005433:0.009085:0.005615:0.011756:0.003684:0.011162:0.011302:0.009039:0.011596:0.010820:0.006437:0.009724:0.011071:0.005547:0.008994:0.003684:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.007989:0.004497:0.003687:0.006894:0.011756:0.003684:0.009291:0.011322:0.011391:0.005273:0.006437:0.005547:0.010843:0.011756:0.003687:0.006209:0.011048:0.003684:0.009656:0.009039:0.011596:0.009131:0.006437:0.005547:0.008994:0.003687:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.009724:0.003684:0.005615:0.011756:0.003687:0.009656:0.009039:0.011596:0.009039:0.007670:0.003684:0.007442:0.009131:0.011505:0.010843:0.007967:0.006209:0.009108:0.011391:0.003684:0.006211:0.011048:0.004109
influence drug response by the DGIdb, related PDOs also exhibited varying degrees of :@0.147059:0.203588:0.886370:0.203588:0.886370:0.183215:0.147059:0.183215:0.005615:0.011756:0.005638:0.005296:0.011345:0.009039:0.011596:0.008994:0.009039:0.005205:0.011391:0.007967:0.011413:0.009861:0.005205:0.007442:0.009039:0.007512:0.011502:0.010843:0.011619:0.007875:0.009039:0.005205:0.010843:0.009724:0.005205:0.006620:0.011299:0.009039:0.005205:0.016504:0.015682:0.006620:0.011322:0.010249:0.004497:0.005205:0.007444:0.008946:0.005435:0.008811:0.006207:0.009108:0.011391:0.005205:0.011664:0.016504:0.016253:0.007670:0.005205:0.009405:0.005250:0.007875:0.011048:0.005205:0.009108:0.010089:0.011459:0.005547:0.010820:0.005273:0.006209:0.009106:0.011391:0.005205:0.009838:0.009085:0.008400:0.009724:0.005615:0.011459:0.009861:0.005205:0.011322:0.009039:0.009861:0.007442:0.009108:0.009039:0.007670:0.005205:0.010843:0.006209:0.004109
genome-wide heterogeneity at both the SNV and CNA levels (:@0.147059:0.224167:0.664384:0.224167:0.664384:0.203794:0.147059:0.203794:0.009656:0.009039:0.011596:0.010843:0.017485:0.009039:0.007533:0.014723:0.005547:0.011322:0.009039:0.003675:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.009724:0.003675:0.008811:0.006437:0.003675:0.011254:0.010820:0.006620:0.011459:0.003675:0.006620:0.011299:0.009039:0.003675:0.009770:0.016230:0.015089:0.003675:0.009087:0.011596:0.011391:0.003675:0.014678:0.015408:0.014929:0.003675:0.005182:0.009336:0.009633:0.008948:0.005250:0.007670:0.003675:0.006939
Figure 5:@0.664327:0.224167:0.737007:0.224167:0.737007:0.203034:0.664327:0.203034:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.003584:0.010911
). The PDOs have :@0.737010:0.224167:0.886480:0.224167:0.886480:0.203794:0.737010:0.203794:0.006939:0.004497:0.003675:0.011470:0.011311:0.009039:0.003675:0.011667:0.016501:0.016253:0.007670:0.003675:0.011391:0.008925:0.009633:0.009039:0.004109
been sequenced at slightly different passage numbers, therefore the heterogeneity may :@0.147059:0.244745:0.886542:0.244745:0.886542:0.224373:0.147059:0.224373:0.011254:0.009108:0.009039:0.011756:0.005752:0.007873:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.009108:0.011391:0.005752:0.008811:0.006437:0.005752:0.007556:0.005250:0.005615:0.009930:0.011094:0.006620:0.005182:0.009724:0.005752:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.005752:0.011368:0.009291:0.007533:0.007941:0.009201:0.009656:0.009039:0.005741:0.011393:0.011413:0.017394:0.011251:0.009039:0.007624:0.007670:0.004497:0.005752:0.006620:0.011299:0.009039:0.007442:0.009039:0.006026:0.010843:0.007442:0.009039:0.005752:0.006620:0.011299:0.009039:0.005752:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.009724:0.005752:0.017577:0.008925:0.009724:0.004109
also be influenced by tumor content (:@0.147059:0.265324:0.473208:0.265324:0.473208:0.244951:0.147059:0.244951:0.009405:0.005250:0.007875:0.011048:0.006163:0.011254:0.009039:0.006163:0.005615:0.011756:0.005638:0.005296:0.011345:0.009039:0.011596:0.008994:0.009108:0.011391:0.006163:0.010843:0.009724:0.006163:0.006163:0.011413:0.017485:0.010843:0.007807:0.006163:0.008994:0.010843:0.011391:0.006209:0.009039:0.011391:0.006437:0.006163:0.006939
Table S7:@0.473230:0.265324:0.548787:0.265324:0.548787:0.244191:0.473230:0.244191:0.011413:0.009679:0.011528:0.005935:0.009473:0.006026:0.010592:0.010911
) and extended passaging, although we :@0.548790:0.265324:0.886441:0.265324:0.886441:0.244951:0.548790:0.244951:0.006939:0.006163:0.009085:0.011596:0.011391:0.006163:0.009108:0.010089:0.006207:0.009039:0.011596:0.011322:0.009108:0.011391:0.006163:0.011368:0.009291:0.007533:0.007944:0.009199:0.009861:0.005615:0.011459:0.009679:0.004497:0.006163:0.009405:0.004908:0.006620:0.011299:0.010820:0.011413:0.009930:0.011459:0.006163:0.014518:0.009039:0.004109
have previously shown that PDOs remained similar at the genomic level after extended :@0.147059:0.285903:0.886510:0.285903:0.886510:0.265530:0.147059:0.265530:0.011391:0.008925:0.009633:0.009039:0.004771:0.011071:0.007444:0.009334:0.009838:0.005547:0.010820:0.011413:0.007556:0.005182:0.009724:0.004771:0.007556:0.011299:0.010866:0.014723:0.011756:0.004771:0.006620:0.011391:0.008811:0.006437:0.004771:0.011664:0.016504:0.016253:0.007670:0.004771:0.007442:0.009039:0.017577:0.009085:0.005615:0.011596:0.009108:0.011391:0.004771:0.007601:0.005615:0.017645:0.005752:0.005433:0.009085:0.007807:0.004771:0.008811:0.006437:0.004771:0.006620:0.011299:0.009039:0.004771:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.004771:0.005182:0.009336:0.009633:0.008948:0.005250:0.004771:0.009085:0.006197:0.005969:0.009039:0.007807:0.004771:0.009108:0.010089:0.006209:0.009039:0.011596:0.011322:0.009108:0.011391:0.004109
passaging . The average number of unique SNVs and CNAs in all related PDOs were :@0.147059:0.306482:0.886492:0.306482:0.886492:0.286109:0.147059:0.286109:0.011368:0.009291:0.007533:0.007944:0.009199:0.009861:0.005615:0.011459:0.009861:0.018244:0.004497:0.005387:0.011470:0.011311:0.009039:0.005387:0.008925:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.005387:0.011391:0.011413:0.017394:0.011254:0.009039:0.007807:0.005387:0.010843:0.006209:0.005387:0.011413:0.011756:0.005547:0.010706:0.011345:0.009039:0.005387:0.009770:0.016230:0.015089:0.007670:0.005387:0.009085:0.011596:0.011391:0.005387:0.014678:0.015408:0.014586:0.007670:0.005387:0.005615:0.011756:0.005387:0.009405:0.005387:0.005250:0.005387:0.007442:0.008948:0.005433:0.008811:0.006209:0.009108:0.011391:0.005387:0.011664:0.016504:0.016253:0.007670:0.005387:0.014518:0.009039:0.007442:0.009039:0.004109
278:@0.229189:0.298866:0.247434:0.298866:0.247434:0.286988:0.229189:0.286988:0.006082:0.006082:0.006082
24% (2 to 70%) and 17% (0 to 100%), respectively. Considerable genomic heterogeneity :@0.147059:0.327060:0.886530:0.327060:0.886530:0.306687:0.147059:0.306687:0.010432:0.010432:0.015043:0.004862:0.006939:0.010432:0.004851:0.006209:0.011048:0.004862:0.010432:0.010432:0.015043:0.006939:0.004862:0.009085:0.011596:0.011391:0.004862:0.010432:0.010432:0.015043:0.004851:0.006939:0.010432:0.004862:0.006209:0.011048:0.004862:0.010432:0.010432:0.010432:0.015043:0.006939:0.004497:0.004851:0.007442:0.009039:0.007510:0.011505:0.009108:0.009108:0.006437:0.005547:0.009633:0.008948:0.005182:0.007989:0.004497:0.004862:0.014995:0.010843:0.011621:0.007601:0.005547:0.011320:0.009039:0.007898:0.009108:0.010911:0.005182:0.009039:0.004862:0.009658:0.009039:0.011596:0.010843:0.017645:0.005545:0.008994:0.004851:0.011302:0.009128:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011598:0.009039:0.005271:0.006437:0.009724:0.004109
at SNV level was observed in LGS-2 and MC-3 (30-70% unique SNVs per PDO), while :@0.147059:0.347639:0.886391:0.347639:0.886391:0.327266:0.147059:0.327266:0.008811:0.006437:0.004611:0.009770:0.016230:0.015089:0.004611:0.005184:0.009334:0.009633:0.008948:0.005250:0.004611:0.014723:0.009291:0.007670:0.004611:0.010957:0.010934:0.007875:0.009039:0.008398:0.009635:0.009106:0.011391:0.004611:0.005615:0.011756:0.004611:0.011528:0.015682:0.010112:0.007533:0.010432:0.004611:0.009085:0.011596:0.011391:0.004611:0.019197:0.014678:0.007533:0.010432:0.004611:0.006939:0.010432:0.010432:0.007533:0.010432:0.010432:0.015043:0.004611:0.011413:0.011756:0.005547:0.010706:0.011345:0.009039:0.004611:0.009770:0.016230:0.015089:0.007670:0.004611:0.011505:0.009039:0.007807:0.004611:0.011664:0.016504:0.016412:0.006939:0.004497:0.004611:0.014792:0.011459:0.005750:0.005182:0.009039:0.004109
these PDOs exhibited differential drug response to only one/two drugs. On the other :@0.147059:0.368218:0.886459:0.368218:0.886459:0.347845:0.147059:0.347845:0.006620:0.011299:0.009039:0.007875:0.009039:0.006129:0.011664:0.016504:0.016253:0.007670:0.006129:0.009108:0.010089:0.011459:0.005545:0.010820:0.005273:0.006209:0.009108:0.011391:0.006129:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.005798:0.009405:0.005250:0.006129:0.011391:0.007967:0.011413:0.009861:0.006129:0.007442:0.009039:0.007510:0.011502:0.010845:0.011619:0.007873:0.009039:0.006129:0.006209:0.011048:0.006129:0.010845:0.011868:0.005184:0.009724:0.006127:0.010843:0.011598:0.009039:0.007099:0.006437:0.014516:0.011048:0.006129:0.011391:0.007967:0.011413:0.009724:0.007670:0.004497:0.006129:0.016298:0.011756:0.006129:0.006620:0.011299:0.009039:0.006129:0.010820:0.006620:0.011299:0.009039:0.007807:0.004109
hand, END-1 and LGS-5 had the lowest degree of genomic heterogeneity (2-14% unique :@0.147059:0.388796:0.886514:0.388796:0.886514:0.368423:0.147059:0.368423:0.011391:0.009085:0.011596:0.011117:0.004497:0.003629:0.012098:0.016230:0.016139:0.007533:0.010432:0.003629:0.009085:0.011598:0.011391:0.003629:0.011528:0.015682:0.010112:0.007533:0.010432:0.003629:0.011391:0.009291:0.011391:0.003629:0.006620:0.011299:0.009039:0.003629:0.005182:0.010868:0.014516:0.009039:0.007512:0.006437:0.003629:0.011322:0.009039:0.009861:0.007442:0.009108:0.009039:0.003629:0.010843:0.006209:0.003629:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.003629:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.009724:0.003629:0.006939:0.010432:0.007533:0.010432:0.010432:0.015043:0.003629:0.011413:0.011756:0.005547:0.010706:0.011345:0.009039:0.004109
SNVs per PDO) and exhibited heterogeneous response to three drugs. In conclusion, we :@0.147059:0.409375:0.886416:0.409375:0.886416:0.389002:0.147059:0.389002:0.009770:0.016230:0.015089:0.007670:0.003721:0.011502:0.009039:0.007807:0.003721:0.011664:0.016504:0.016412:0.006939:0.003721:0.009085:0.011596:0.011391:0.003721:0.009108:0.010089:0.011459:0.005547:0.010820:0.005273:0.006209:0.009108:0.011391:0.003721:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009108:0.010820:0.011413:0.007670:0.003721:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.003721:0.006211:0.011048:0.003721:0.006620:0.011459:0.007442:0.009108:0.009039:0.003721:0.011391:0.007964:0.011413:0.009724:0.007670:0.004497:0.003721:0.006894:0.011756:0.003721:0.008994:0.010843:0.011596:0.008765:0.004908:0.011413:0.007601:0.005547:0.010843:0.011756:0.004497:0.003721:0.014518:0.009039:0.004109
did not observe a direct correlation between genome-wide heterogeneity and differential :@0.147059:0.429954:0.886464:0.429954:0.886464:0.409581:0.147059:0.409581:0.011391:0.005547:0.011391:0.003435:0.011596:0.010820:0.006437:0.003435:0.010957:0.010934:0.007875:0.009039:0.008400:0.009633:0.009039:0.003435:0.009291:0.003435:0.011391:0.005615:0.007442:0.009108:0.009108:0.006437:0.003435:0.008994:0.010843:0.007807:0.007442:0.008948:0.005433:0.008811:0.006437:0.005547:0.010843:0.011756:0.003435:0.011254:0.009131:0.006437:0.014518:0.009108:0.009039:0.011756:0.003435:0.009656:0.009039:0.011596:0.010843:0.017485:0.009039:0.007533:0.014723:0.005547:0.011322:0.009039:0.003435:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.009724:0.003435:0.009085:0.011596:0.011391:0.003435:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.005798:0.009405:0.005250:0.004109
drug response.:@0.147059:0.450532:0.270871:0.450532:0.270871:0.430160:0.147059:0.430160:0.011391:0.007967:0.011413:0.009861:0.004109:0.007442:0.009039:0.007510:0.011502:0.010845:0.011619:0.007875:0.008743:0.004497
Discussion:@0.147059:0.518926:0.261641:0.518926:0.261641:0.490815:0.147059:0.490815:0.013103:0.006217:0.012144:0.012841:0.013015:0.012144:0.012144:0.006217:0.013132:0.013626
We have performed drug screening on 36 PDOs derived from 23 patients comprising all :@0.147059:0.563568:0.886576:0.563568:0.886576:0.543195:0.147059:0.543195:0.018649:0.009039:0.003881:0.011391:0.008925:0.009633:0.009039:0.003881:0.011502:0.009039:0.007807:0.006026:0.010843:0.007807:0.017485:0.009108:0.011391:0.003881:0.011391:0.007967:0.011413:0.009861:0.003881:0.007875:0.008994:0.007442:0.009108:0.009039:0.011756:0.005615:0.011459:0.009861:0.003881:0.010843:0.011756:0.003881:0.010432:0.010432:0.003881:0.011664:0.016504:0.016253:0.007670:0.003881:0.011322:0.009039:0.007807:0.005547:0.009633:0.009108:0.011391:0.003881:0.006414:0.007442:0.010843:0.017645:0.003881:0.010432:0.010432:0.003881:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.003881:0.008994:0.010843:0.017280:0.011071:0.007807:0.005615:0.007601:0.005615:0.011459:0.009861:0.003881:0.009405:0.005387:0.005250:0.004109
major OC histopathological subtypes. OC PDOs resembled the tumors they were de-:@0.147059:0.584147:0.882353:0.584147:0.882353:0.563774:0.147059:0.563774:0.017577:0.008811:0.005341:0.010843:0.007807:0.005901:0.016775:0.014678:0.005901:0.011459:0.005615:0.007510:0.006209:0.010820:0.011368:0.008811:0.006620:0.011299:0.010934:0.005182:0.011048:0.009861:0.005547:0.009108:0.009405:0.005250:0.005898:0.007510:0.011345:0.010797:0.006437:0.009724:0.011505:0.009039:0.007670:0.004497:0.005898:0.016778:0.014678:0.005901:0.011664:0.016504:0.016253:0.007670:0.005898:0.007442:0.009039:0.007875:0.009039:0.017394:0.010911:0.005182:0.009108:0.011391:0.005901:0.006620:0.011299:0.009039:0.005901:0.006163:0.011413:0.017485:0.010843:0.007624:0.007670:0.005898:0.006620:0.011302:0.009334:0.009724:0.005901:0.014518:0.009039:0.007442:0.009039:0.005901:0.011322:0.009037:0.007533
rived from, with an average overlap of 67% of SNVs and similar CNA profiles. PDOs :@0.147059:0.604726:0.886555:0.604726:0.886555:0.584353:0.147059:0.584353:0.007807:0.005547:0.009633:0.009108:0.011391:0.006140:0.006414:0.007442:0.010843:0.017645:0.004497:0.006140:0.014723:0.005273:0.006620:0.011459:0.006140:0.009085:0.011756:0.006140:0.008925:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.006140:0.010866:0.009633:0.009039:0.007601:0.005433:0.008811:0.011276:0.006140:0.010843:0.006209:0.006140:0.010432:0.010432:0.015043:0.006140:0.010843:0.006209:0.006140:0.009770:0.016230:0.015089:0.007670:0.006140:0.009085:0.011596:0.011391:0.006140:0.007604:0.005615:0.017645:0.005750:0.005433:0.009085:0.007807:0.006140:0.014678:0.015408:0.014929:0.006140:0.011071:0.007442:0.010845:0.005684:0.005819:0.005182:0.009039:0.007670:0.004497:0.006140:0.011664:0.016504:0.016253:0.007670:0.004109
generated at interval debulking recapitulated clinical response to first-line carboplatin :@0.147059:0.625304:0.886434:0.625304:0.886434:0.604932:0.147059:0.604932:0.009656:0.009039:0.011596:0.009039:0.007898:0.008811:0.006209:0.009108:0.011391:0.006118:0.008811:0.006437:0.006118:0.005615:0.011388:0.006211:0.009039:0.008398:0.009838:0.009405:0.005250:0.006118:0.011322:0.008902:0.010797:0.011550:0.005387:0.010706:0.005615:0.011459:0.009861:0.006118:0.007442:0.009108:0.009108:0.008811:0.011071:0.005273:0.006163:0.011550:0.005433:0.008811:0.006209:0.009108:0.011391:0.006118:0.008765:0.005250:0.005615:0.011756:0.005547:0.009108:0.009405:0.005250:0.006118:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.006118:0.006209:0.011048:0.006118:0.005684:0.005684:0.007622:0.007510:0.006437:0.007533:0.005250:0.005615:0.011596:0.009039:0.006118:0.009106:0.009087:0.007715:0.011251:0.010820:0.011162:0.005433:0.008811:0.006437:0.005615:0.011756:0.004109
and paclitaxel combination treatment for histopathological (p=5.821e-05), biochemical :@0.147059:0.645883:0.886418:0.645883:0.886418:0.625510:0.147059:0.625510:0.009085:0.011596:0.011391:0.004611:0.011368:0.009291:0.008765:0.005250:0.005273:0.006551:0.009291:0.009884:0.008948:0.005250:0.004611:0.008994:0.010843:0.017394:0.010820:0.005615:0.011687:0.008811:0.006437:0.005547:0.010843:0.011756:0.004611:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.004611:0.006026:0.010843:0.007807:0.004611:0.011459:0.005615:0.007510:0.006209:0.010820:0.011368:0.008811:0.006620:0.011299:0.010934:0.005182:0.011048:0.009861:0.005547:0.009108:0.009405:0.005250:0.004611:0.006939:0.011276:0.011779:0.010432:0.004497:0.010432:0.010432:0.010432:0.009039:0.007533:0.010432:0.010432:0.006939:0.004497:0.004611:0.010820:0.005547:0.011276:0.008765:0.011299:0.009039:0.017645:0.005547:0.009108:0.009405:0.005250:0.004109
(p=0.0004) and radiological (p=0.0092) outcomes.:@0.147059:0.666462:0.569827:0.666462:0.569827:0.646089:0.147059:0.646089:0.006939:0.011276:0.011779:0.010432:0.004497:0.010432:0.010432:0.010432:0.010432:0.006939:0.004109:0.009083:0.011596:0.011391:0.004109:0.007898:0.009291:0.011391:0.005547:0.010934:0.005182:0.011048:0.009861:0.005545:0.009108:0.009405:0.005250:0.004109:0.006939:0.011276:0.011779:0.010432:0.004497:0.010432:0.010432:0.010432:0.010432:0.006939:0.004109:0.010818:0.011071:0.006209:0.008994:0.010843:0.017485:0.009039:0.007670:0.004497
Diverse responses to registered drugs for OC were observed among PDOs. Low respon-:@0.147059:0.707619:0.882353:0.707619:0.882353:0.687246:0.147059:0.687246:0.016024:0.005547:0.009633:0.009039:0.007624:0.007875:0.009039:0.003995:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.007670:0.003995:0.006209:0.011048:0.003995:0.007442:0.009039:0.009861:0.005615:0.007510:0.006209:0.009039:0.007442:0.009108:0.011391:0.003995:0.011391:0.007967:0.011413:0.009724:0.007670:0.003995:0.006026:0.010843:0.007807:0.003995:0.016778:0.014678:0.003995:0.014518:0.009039:0.007442:0.009039:0.003995:0.010957:0.010932:0.007875:0.009039:0.008400:0.009633:0.009108:0.011391:0.003995:0.009087:0.017485:0.010843:0.011459:0.009861:0.003995:0.011664:0.016504:0.016253:0.007670:0.004497:0.003995:0.011824:0.010866:0.014723:0.003995:0.007442:0.009039:0.007510:0.011502:0.010845:0.011845:0.007533
siveness to first-line carboplatin (7/31, 23%) and paclitaxel (5/31, 16%) treatment was :@0.147059:0.728198:0.886553:0.728198:0.886553:0.707825:0.147059:0.707825:0.007601:0.005547:0.009633:0.009039:0.011596:0.009039:0.007533:0.007670:0.006323:0.006209:0.011048:0.006323:0.005684:0.005684:0.007624:0.007510:0.006437:0.007533:0.005250:0.005615:0.011596:0.009039:0.006323:0.009108:0.009085:0.007715:0.011251:0.010820:0.011162:0.005433:0.008811:0.006437:0.005615:0.011756:0.006323:0.006939:0.010432:0.007099:0.010432:0.010432:0.004497:0.006323:0.010432:0.010432:0.015043:0.006939:0.006323:0.009085:0.011596:0.011391:0.006323:0.011368:0.009291:0.008765:0.005250:0.005273:0.006551:0.009291:0.009884:0.008948:0.005250:0.006323:0.006939:0.010432:0.007099:0.010432:0.010432:0.004497:0.006323:0.010432:0.010432:0.015043:0.006939:0.006323:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.006323:0.014723:0.009291:0.007670:0.004109
observed, compared to high responsiveness in the majority of patients to second-line :@0.147059:0.748777:0.886368:0.748777:0.886368:0.728404:0.147059:0.728404:0.010957:0.010934:0.007875:0.009039:0.008400:0.009633:0.009106:0.011117:0.004497:0.006437:0.008994:0.010843:0.017280:0.011368:0.009085:0.007442:0.009108:0.011391:0.006437:0.006209:0.011048:0.006437:0.011459:0.005615:0.009930:0.011459:0.006437:0.007442:0.009039:0.007510:0.011502:0.010845:0.011619:0.007601:0.005547:0.009633:0.009039:0.011596:0.009039:0.007533:0.007670:0.006437:0.005615:0.011756:0.006437:0.006620:0.011299:0.009039:0.006437:0.017577:0.008811:0.005339:0.010843:0.007807:0.005273:0.006437:0.009724:0.006437:0.010843:0.006209:0.006437:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.006437:0.006209:0.011048:0.006437:0.007873:0.009108:0.008994:0.010843:0.011598:0.011391:0.007533:0.005250:0.005615:0.011596:0.009039:0.004109
gemcitabine treatment (29/35, 83%). All PDOs exposed to PARP-inhibition were found :@0.147059:0.769355:0.886532:0.769355:0.886532:0.748982:0.147059:0.748982:0.009656:0.009039:0.017485:0.008994:0.005273:0.006551:0.009108:0.010820:0.005615:0.011596:0.009039:0.004360:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.004360:0.006939:0.010432:0.010432:0.007099:0.010432:0.010432:0.004497:0.004360:0.010432:0.010432:0.015043:0.006939:0.004497:0.004360:0.015066:0.005387:0.005250:0.004360:0.011664:0.016504:0.016253:0.007670:0.004360:0.009108:0.010089:0.011505:0.010957:0.007875:0.009106:0.011391:0.004360:0.006209:0.011048:0.004360:0.010249:0.014929:0.013376:0.010592:0.007533:0.005615:0.011870:0.011459:0.005547:0.010820:0.005273:0.006437:0.005547:0.010843:0.011756:0.004360:0.014520:0.009039:0.007442:0.009039:0.004360:0.006026:0.010820:0.011413:0.011596:0.011391:0.004109
to be low responsive, in line with HR-proficiency classification based on WGS data. Re-:@0.147059:0.789934:0.882353:0.789934:0.882353:0.769561:0.147059:0.769561:0.006209:0.011048:0.004451:0.011251:0.009039:0.004451:0.005182:0.010866:0.014723:0.004451:0.007442:0.009039:0.007510:0.011502:0.010845:0.011619:0.007601:0.005547:0.009633:0.008743:0.004497:0.004451:0.005615:0.011756:0.004451:0.005250:0.005615:0.011596:0.009039:0.004451:0.014723:0.005273:0.006620:0.011459:0.004451:0.016846:0.012349:0.007533:0.011069:0.007444:0.010843:0.005684:0.005615:0.008994:0.005545:0.009039:0.011598:0.009382:0.009724:0.004451:0.008765:0.005433:0.009291:0.007533:0.007601:0.005615:0.005684:0.005615:0.009108:0.008811:0.006437:0.005547:0.010843:0.011756:0.004451:0.011114:0.009291:0.007875:0.009108:0.011391:0.004451:0.010843:0.011756:0.004451:0.020270:0.015682:0.010112:0.004451:0.011573:0.008811:0.006551:0.009291:0.004497:0.004451:0.013696:0.009087:0.007533
sponse to targeted drugs under clinical investigation could partly be explained by genetic :@0.147059:0.810513:0.886341:0.810513:0.886341:0.790140:0.147059:0.790140:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.003378:0.006209:0.011048:0.003378:0.006551:0.009085:0.007624:0.009656:0.009131:0.006209:0.009108:0.011391:0.003378:0.011391:0.007967:0.011413:0.009724:0.007670:0.003378:0.011413:0.011596:0.011322:0.009039:0.007807:0.003378:0.008765:0.005250:0.005615:0.011756:0.005547:0.009106:0.009405:0.005250:0.003378:0.005615:0.011365:0.009633:0.009039:0.007512:0.006437:0.005615:0.009861:0.008809:0.006437:0.005547:0.010843:0.011756:0.003378:0.008994:0.010818:0.011550:0.005184:0.011391:0.003378:0.011365:0.009087:0.007964:0.006620:0.005182:0.009724:0.003378:0.011251:0.009039:0.003378:0.009108:0.010089:0.011162:0.005433:0.009085:0.005615:0.011598:0.009106:0.011391:0.003378:0.010843:0.009724:0.003378:0.009656:0.009039:0.011596:0.009131:0.006437:0.005547:0.008994:0.004109
variation; low responsiveness to afatinib (12/25, 48%), low responsiveness to adavosertib :@0.147059:0.831091:0.886441:0.831091:0.886441:0.810719:0.147059:0.810719:0.009838:0.009085:0.007807:0.005798:0.008811:0.006437:0.005547:0.010843:0.011756:0.004497:0.003721:0.005182:0.010866:0.014723:0.003721:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007601:0.005547:0.009633:0.009039:0.011596:0.009039:0.007533:0.007670:0.003721:0.006209:0.011048:0.003721:0.009085:0.006209:0.008811:0.006437:0.005615:0.011756:0.005547:0.011025:0.003721:0.006939:0.010432:0.010432:0.007099:0.010432:0.010432:0.004497:0.003721:0.010432:0.010432:0.015043:0.006939:0.004497:0.003721:0.005182:0.010866:0.014723:0.003721:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007601:0.005547:0.009633:0.009039:0.011596:0.009039:0.007533:0.007670:0.003721:0.006209:0.011048:0.003721:0.009291:0.011573:0.008925:0.009633:0.010957:0.007875:0.009039:0.007967:0.006437:0.005547:0.011025:0.004109
(7/17, 41%), high responsiveness to flavopiridol (N=4/17, 24%) and high responsiveness :@0.147059:0.851670:0.886443:0.851670:0.886443:0.831297:0.147059:0.831297:0.006939:0.010432:0.007099:0.010432:0.010432:0.004497:0.004154:0.010432:0.010432:0.015043:0.006939:0.004497:0.004154:0.011459:0.005615:0.009930:0.011459:0.004154:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007601:0.005547:0.009633:0.009039:0.011596:0.009039:0.007533:0.007670:0.004154:0.006209:0.011048:0.004154:0.005638:0.005821:0.008925:0.009633:0.010822:0.011069:0.005615:0.007807:0.005547:0.011322:0.010934:0.005250:0.004154:0.006939:0.016230:0.011779:0.010432:0.007099:0.010432:0.010432:0.004497:0.004154:0.010432:0.010432:0.015043:0.006939:0.004154:0.009087:0.011596:0.011391:0.004154:0.011459:0.005615:0.009930:0.011459:0.004154:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007601:0.005547:0.009633:0.009039:0.011596:0.009039:0.007533:0.007670:0.004109
to vemurafenib (5/7, 71%). Importantly, we identified a high responsiveness to at least :@0.147059:0.872249:0.886544:0.872249:0.886544:0.851876:0.147059:0.851876:0.006209:0.011048:0.005798:0.009633:0.009039:0.017280:0.011413:0.007898:0.009085:0.006026:0.009039:0.011756:0.005547:0.011025:0.005798:0.006939:0.010432:0.007099:0.010432:0.004497:0.005787:0.010432:0.010432:0.015043:0.006939:0.004497:0.005787:0.006894:0.017280:0.011505:0.010843:0.007967:0.006551:0.009085:0.011391:0.006620:0.005182:0.007989:0.004497:0.005798:0.014518:0.009039:0.005798:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.005684:0.005613:0.009108:0.011391:0.005798:0.009291:0.005798:0.011459:0.005615:0.009930:0.011459:0.005787:0.007442:0.009039:0.007512:0.011502:0.010843:0.011619:0.007601:0.005549:0.009633:0.009039:0.011596:0.009039:0.007533:0.007670:0.005798:0.006209:0.011048:0.005798:0.008811:0.006437:0.005798:0.005182:0.009291:0.009291:0.007510:0.006437:0.004109
one tested drug in nearly all patients (22/25, 88%). Since not all PDOs were exposed to :@0.147059:0.892828:0.886505:0.892828:0.886505:0.872455:0.147059:0.872455:0.010843:0.011596:0.009039:0.005056:0.006211:0.009039:0.007510:0.006209:0.009106:0.011391:0.005068:0.011391:0.007967:0.011413:0.009861:0.005056:0.005615:0.011756:0.005056:0.011596:0.009291:0.009085:0.007601:0.005182:0.009724:0.005068:0.009405:0.005387:0.005250:0.005056:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.005056:0.006939:0.010432:0.010432:0.007099:0.010432:0.010432:0.004497:0.005056:0.010432:0.010432:0.015043:0.006939:0.004497:0.005054:0.010112:0.005615:0.011596:0.008994:0.009039:0.005068:0.011596:0.010820:0.006437:0.005056:0.009405:0.005387:0.005250:0.005056:0.011667:0.016501:0.016253:0.007670:0.005068:0.014518:0.009039:0.007442:0.009039:0.005056:0.009108:0.010089:0.011505:0.010957:0.007873:0.009108:0.011391:0.005068:0.006209:0.011048:0.004109
the same number of drugs (3-13 monotherapies tested per patient), this is likely an un-:@0.147059:0.913406:0.882353:0.913406:0.882353:0.893034:0.147059:0.893034:0.006620:0.011299:0.009039:0.004862:0.007944:0.009085:0.017485:0.009039:0.004862:0.011391:0.011413:0.017394:0.011254:0.009039:0.007807:0.004862:0.010843:0.006209:0.004862:0.011391:0.007967:0.011413:0.009724:0.007670:0.004862:0.006939:0.010432:0.007533:0.010432:0.010432:0.004862:0.017485:0.010843:0.011596:0.010820:0.006620:0.011302:0.009039:0.007896:0.008811:0.011071:0.005547:0.009039:0.007670:0.004862:0.006209:0.009039:0.007510:0.006209:0.009108:0.011391:0.004862:0.011505:0.009039:0.007807:0.004862:0.011365:0.008813:0.006437:0.005545:0.009039:0.011391:0.006437:0.006939:0.004497:0.004862:0.006620:0.011459:0.005615:0.007670:0.004862:0.005615:0.007670:0.004862:0.005250:0.005752:0.010272:0.008948:0.005182:0.009724:0.004862:0.009085:0.011756:0.004862:0.011413:0.011847:0.007533